Atlanta Consulting Group Advisors LLC Buys New Position in Sanofi (NASDAQ:SNY)

Atlanta Consulting Group Advisors LLC purchased a new position in shares of Sanofi (NASDAQ:SNY) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 19,272 shares of the company’s stock, valued at approximately $1,111,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. POM Investment Strategies LLC bought a new stake in Sanofi during the second quarter worth about $25,000. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners raised its stake in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares in the last quarter. Arrow Financial Corp bought a new stake in shares of Sanofi during the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after buying an additional 659 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $47.97 on Friday. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a market capitalization of $121.74 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 1.22 and a beta of 0.61. The company has a 50-day simple moving average of $54.65 and a 200 day simple moving average of $52.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.55 earnings per share. On average, sell-side analysts predict that Sanofi will post 4.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SNY. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Argus upped their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.